The revolution of Nutraceuticals through FM-LipoMatrix® technology.

All products in the Norm Line are made with the finest raw materials, which undergo multiple stages of microbiological testing, both in vivo and in vitro, to ensure safety and stability, confirming the complete absence of pesticides, radioactive residues, and chemical contaminants. Production takes place in clean rooms with constantly filtered air to prevent contamination, while temperature and humidity are carefully monitored to guarantee impeccable quality.

The production process follows the strictest GMP (Good Manufacturing Practices) standards for dietary supplements, as established by the World Health Organization (WHO).

The Norm Line is the result of a truly revolutionary, patented technology that we have named FM-LipoMatrix®.
It is a blend of vegetable oils complexed with specific components, endowed with its own biological activity, capable of enhancing the effectiveness of lipophilic substances in nutraceutical (and pharmaceutical) formulations.

But that’s not all—FM-LipoMatrix® also provides:
– greater water solubility of fat-soluble substances and superior stability of active components;
– optimized intestinal absorption and increased bioavailability of ingredients, from 50% up to 300%, thanks to an advanced delivery system;
– a drastic reduction in side effects caused by high dosages.

All active ingredients are first subjected to the fluidization process: a bed of particles in the product container is transformed into a fluid-like state by an upward flow of liquid or gas. Once the bed is fully fluidized, the granulation liquid is added—this is the FM-LipoMatrix® technology.

A New Palmitoylethanolamide Form Combined with Antioxidant Molecules to Improve Its Effectivess on Neuronal Aging

Vera Morsanuto *, Rebecca Galla, Claudio Molinari † and Francesca Uberti *,† Laboratory of Physiology, Department of Translational Medicine, University of Piemonte Orientale, Italy
8 May 2020; Accepted: 9 July 2020; Published: 17 July 2020

Palmitoylethanolamide (PEA) is a long-chain fatty acid amide, formed by the combination of palmitic acid and an ethanolamine group.

It is a molecule with highly interesting active properties in cases of chronic or acute pain and inflammation: rather than binding directly to endocannabinoid receptors, it acts as a mediator, contributing to the biological response of endogenous cannabinoids and preventing their degradation, thereby prolonging their action against pain.

Notably, Professor Rita Levi Montalcini was among the most eminent scientific voices in Italy to highlight the therapeutic value of PEA: “Palmitoylethanolamide is orally active in reducing tissue inflammation and mast cell degranulation in vivo, decreasing the hyperalgesia associated with peripheral nerve compression.”*.
PEA demonstrates significant anti-inflammatory, analgesic, immunomodulatory, and neuroprotective effects, contributing to the restoration of homeostasis in glutamatergic transmission. Furthermore, PEA’s ability to modulate protective responses during inflammation derives from its role within the homeostatic system that regulates inflammation, counteracting the release of newly synthesized inflammatory mediators from activated mast cells.

Numerous studies and ongoing research highlight the potential of this molecule in the anti-inflammatory and analgesic treatment of various clinical conditions—without side effects.**

The only drawback in an otherwise exceptional profile is its low bioavailability.
This is where FM-LipoMatrix® comes into play—and where the products Artonorm and Peanorm are born.

* Levi-Montalcini R; Trends Neurosci. 1996 Nov;19(11):514-20. Review

** Review: The Basal Pharmacology of Palmitoylethanolamide
Linda Rankin † and Christopher J. Fowler * Department of Integrative Medical Biology, Umeå University, SE-901 87 Umeå, Sweden;
Published: 26 October 2020

The Innovation of Hyaluronic Acid for Joint Health

Hyaluronic Acid plays a fundamental role in the health and stability of the joint environment: the positive response to the stresses required by movement and natural variations in load largely depends on its presence, both in terms of quantity and quality. In individuals with osteoarthritis, for example, the molecular weight and concentration of Hyaluronic Acid are reduced, leading to cartilage degeneration.

To address this issue, LeadingMed has developed the Reviscon Line and the Vis Line, leveraging the unique viscous and elastic properties of a truly innovative Hyaluronic Acid, the result of intensive scientific research and specialized studies.

– The REVISCON LINE offers an infiltrative therapy with high molecular weight Hyaluronic Acid of a new generation, highly biocompatible and purified.

Reviscon consists of highly purified, high molecular weight Sodium Hyaluronate dissolved in physiological saline solution.
All synovial joints naturally contain viscoelastic Sodium Hyaluronate, particularly weight-bearing joints. In patients with osteoarthritis, however, the viscoelasticity of synovial fluid is significantly reduced. This causes mechanical stress on the joint, leading to the breakdown of articular cartilage, limiting mobility and causing considerable pain.

Through its range of products, the Reviscon Line alleviates pain while improving overall mobility: in fact, the complex viscosity typical of Hyaluronic Acid provides both viscous and elastic properties, which are essential for joint health.
The excellent rheological profile of the Reviscon Line ensures optimal viscosity at rest (up to five times higher than many comparable products on the market), and thus an equally optimal reduction in pain thanks to superior dynamic elasticity under high stress.

– Reviscon 20 mg in 2 ml: 3–5 infiltrations for gradual therapy;
– Reviscon Mono 48 mg in 2.4 ml: single infiltration, high performance;
– Reviscon Plus 32 mg in 2 ml: high efficacy with 2–3 infiltrations.

The VIS LINE offers an infiltrative therapy based on Hyaluronic Acid, specifically designed to reduce symptoms and inflammatory conditions, while increasing lubrication and visco-induction within the joint environment.

RenehaVis (LMW–HMW Mix, dual chamber) – 1 to 3 infiltrations per week
RenehaVis consists of a sterile, pre-filled dual-chamber glass syringe, ready to use, containing:

– Chamber 1: Low Molecular Weight (LMW) Sodium Hyaluronate – 0.7 ml of sterile Sodium Hyaluronate 2.2%, molecular weight 1 × 10⁶ Da.
– Chamber 2: High Molecular Weight (HMW) Sodium Hyaluronate – 0.7 ml of sterile Sodium Hyaluronate 1.0%, molecular weight 2 × 10⁶ Da.

RenehaVis is particularly effective in reducing knee joint pain and stiffness in patients affected by synovial joint degeneration.

The high reliability of RenehaVis is due to its physicochemical properties: the LMW and HMW Sodium Hyaluronate contained in RenehaVis is a biopolymer composed of disaccharide units of N-acetylglucosamine and glucuronic acid, obtained through the biosynthesis of Streptococcus equi. It is identical to the Sodium Hyaluronate naturally found in synovial joints, but which may have been altered by degenerative or traumatic changes within the synovial joint.

RenehaVis supplements the synovial Sodium Hyaluronate that has undergone alterations in molecular weight and concentration.

TendoVis (Soft Tissue Adapted Biocompatible Hyaluronic Acid) – 2 infiltrations (one per week)
TendoVis is indicated for periarticular infiltrations in cases of damaged or compromised tendons and ligaments.

– modulates inflammation
– reduces pain
– protects and supports the injured area
– lowers the risk of recurrence
– shortens recovery times
– promotes proper tendon realignment, leading to functional recovery.

TendoVis is a sterile glass syringe containing Sodium Hyaluronate with pH and osmolarity biocompatible with soft tissues. It is therefore suitable for periarticular injection, specifically in the soft tissues surrounding tendons and ligaments.

TendoVis is indicated for patients with rotator cuff tendinopathy, epicondylitis, and ankle sprains. Thanks to a sophisticated patented manufacturing process (STABHA patent – Soft Tissue Adapted Biocompatible Hyaluronic Acid), it ensures prolonged retention time and prevents degradative reactions by the body (thanks to the absence of endotoxins and nucleic acids).

*The I.D.E.H.A. Study Intra-articular Double Molecular Weight Efficacy of Hyaluronic Acid

Authors: Dr. Romeo Gatti, Xuming Shen – IDEHA Group
Patients: 1,214 patients in Italy (Multicenter study involving over 50 physicians) PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24416477
SAFETY AND EFFICACY IN PAIN REDUCTION

Long term efficacy and safety of a combined low and high molecular weight hyaluronic acid in the treatment of osteoarthritis of the knee
Authors: Robert J. Petrella, Joseph Decaria, Michael Petrella
PubMed: http://www.pagepress.org/journals/index.php/rr/article/view/rr.2011.e4/2729

EULAR ROME 2010

LONG-TERM EFFICACY (12–24 MONTHS) AND GREATER EFFECTIVENESS COMPARED TO CONVENTIONAL THERAPIES
Efficacy of DualVis (Renehavis) for Knee Osteoarthritis in Indonesia
Authors: Prof. Handono Kalim, Dr. Arif Sumardjono, Dr. Nyimas Fatimah.